Treatment Options
516 articles
Tumor Subtypes Potentially Provide Clues About Prognosis and Treatment
Drs. Andrew Aguirre and David Ting are teasing out the differences between pancreatic cancer subtypes, to get treatments that work better.
Maintenance Chemotherapy for Stable Metastatic Pancreatic Cancer
A clinical trial tests the diabetes drug metformin and transplant rejection preventative rapamycin to act as maintenance chemotherapy for pancreatic cancer.
Testing Treatment Combinations to Make Surgery More Effective
Can losartan (a high blood pressure drug) and immunotherapy combined with standard chemotherapy and radiation be an effective combination against pancreatic cancer?
Pancreatic Cancer Exceptional Responders and the Immune System Link
Dr. Vinod Balachandran looks at the immune system of exceptional responders–patients who respond extremely well to chemotherapy–for treatment clues.
Steven Merlin and Davi D’Agostino Team Up to Help Others
Pancreatic cancer patient advocates Steven Merlin and Davi D’Agostino have joined to pool expertise and information for other patients.
My Eight-Year Un-Celebration of Surviving Pancreatic Cancer
William Ramshaw shares his thoughts and advice for those in treatment, on reaching the eight-year pancreatic cancer survivor mark.
ASCO Annual Conference: Highlights in Pancreatic Cancer Research
Dr. Allyson Ocean reviews some of the latest pancreatic cancer research results, including new treatments for some patients.
Comparing the Effectiveness of Vaccine Therapy With or Without Additional Immunotherapy
Can the immunotherapy combination of cancer vaccines and a checkpoint blockade drug work against metastatic pancreatic cancer?
Finding the Best Diabetes Drug for Pancreatic Cancer Patients
With all the various drugs out there, Dr. James Flory wants to establish which diabetes drug works best for pancreatic cancer patients. Read his expert advice.
Targeted Therapy for Cancers Carrying the PALB2 Mutation
Researchers are testing a type of targeted therapy called a PARP inhibitor for cancers carrying the PALB2 mutation.